Category: Pharmaceuticals
Global Pharmaceuticals
-
Pharmacovigilance
... 9.3% over the analysis period 2024-2030. Contract Outsourcing Service Provider, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$12.3 Billion by the end of the analysis ... Read More
-
Pesticide Inert Ingredients
... at a CAGR of 6.2% over the analysis period 2024-2030. Emulsifiers, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$3.3 Billion by the end of the ... Read More
-
Probiotics Dietary Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Capsules Form, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$4.2 Billion by the end of ... Read More
-
Soft Tissue Repair
... at a CAGR of 6.0% over the analysis period 2024-2030. Fixation Products, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$19.6 Billion by the end of ... Read More
-
Therapeutic Respiratory Devices
... at a CAGR of 3.3% over the analysis period 2024-2030. Positive Airway Pressure Devices, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$32.3 Billion by the ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Prenatal Diagnostics
... CAGR of 12.8% over the analysis period 2024-2030. Non-Invasive Test, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$10.6 Billion by the end of the analysis ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Chiropractic Care
... CAGR of 3.6% over the analysis period 2024-2030. Relief Care, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$25.6 Billion by the end of the analysis ... Read More
-
Clinical Trial Management Systems (CTMS)
... Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2024-2030. Enterprise-Wide CTMS, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$3.1 Billion ... Read More
-
H1N1 Vaccines
... CAGR of 5.4% over the analysis period 2024-2030. Intramuscular Vaccines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.1 Billion by the end of the analysis ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of ... Read More
-
Clinical Nutrition Products
... at a CAGR of 4.0% over the analysis period 2024-2030. Oral Nutrition, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$28.7 Billion by the end of ... Read More
-
Hormone Replacement Therapy (HRT)
... 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Estrogen Hormone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$24.2 Billion ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. HCS Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the ... Read More
-
Heart Healthy Ingredients
... at a CAGR of 4.2% over the analysis period 2024-2030. Omega-3 Ingredient, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$12.4 Billion by the end of ... Read More
-
Glucosamine
... 6.9% over the analysis period 2024-2030. Nutritional Supplements Application, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.2 Billion by the end of the analysis period. ... Read More
-
Dental Preventive Supplies
... at a CAGR of 4.3% over the analysis period 2024-2030. The U.S. Market is Estimated at US$156.3 Million While China is Forecast to Grow at 6.4% CAGR The Dental Preventive Supplies market in the U.S. ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the ... Read More
-
Wearable Fitness Technology
... at a CAGR of 13.3% over the analysis period 2024-2030. Smartwatches, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$11.0 Billion by the end of the ... Read More
-
Sleep Apnea Diagnostic and Therapeutic Devices
... reach US$14.0 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Diagnostic Devices, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach ... Read More
-
Cholesterol Testing
... CAGR of 4.4% over the analysis period 2024-2030. Diagnostic Centers End-Use, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$11.6 Billion by the end of the ... Read More
-
Anti-Hypertensive Drugs
... CAGR of 2.7% over the analysis period 2024-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the ... Read More
-
Gastrointestinal (GI) Endoscopy Devices
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$25.5 ... Read More
Research Assistance
